Parallels Between Major Depressive Disorder and Alzheimer’s Disease: Role of Oxidative Stress and Genetic Vulnerability

Cellular and Molecular Neurobiology

Volumn 34, Issue 7, 2014, Pages 925-949

  Rodrigues, Roberto ^a   Petersen, Robert B ^b   Perry, George ^c  

^a University of San Antonio   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Alzheimer s disease; Amyloid ; Lipid peroxidation; Major depressive disorder; Nucleic acid oxidation; Oxidative stress; Tau

Indexed keywords

CHEMOKINE;

ALZHEIMER DISEASE; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; GENETICS; HIPPOCAMPUS; HUMAN; MENTAL STRESS; METABOLISM; OXIDATIVE STRESS; PATHOLOGY;

ALZHEIMER DISEASE; CHEMOKINES; DEPRESSIVE DISORDER, MAJOR; HIPPOCAMPUS; HUMANS; OXIDATIVE STRESS; STRESS, PSYCHOLOGICAL;

EID: 84930278819     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-014-0074-5     Document Type: Review

References (208)

1. Akiskal HS, Lewis LJ (2005) The depressive spectrum: re-conceptualizing the relationship between dysthymic, sub-threshold and major depressions. In: Licinio J, Wong M-L (eds.) Biology of depression: from novel insights to therapeutic strategies. Wiley-VCH Verlag GmbH & Co., Weinheim GmbH & Co., Weinheim, pp 47–70
2. Akiskal HS, McKinney WTJ (1973) Depressive disorders: toward a unified hypothesis. Science 182:20–29
3. Alexopoulos G, Young R, Meyers B (1993) Geriatric depression: age of onset and dementia. Biol Psychiatry 1934:141–145
4. Allagy MS, Nciri R, Rouhayd MF, Mourat GC, El Feki A, Croute D, Vincent C (2009) Long term exposure to low lithium concentrations stimulates proliferation, modifies stress protein expression pattern and enhances resistance to oxidative stress in SH-SY5Y cells. Neurochem Res 34:453–462
5. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotrophin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1–12
6. Atwood CS, Meethal SV, Liu T, Wilson AC, Gallego M, Smith MA, Bowen RL (2005) Dysregulation of the hypothalamic-pituitary-gonadal axis wit menopause and andropause promotes neurodegenerative senescence. J Neuropathol Exp Neurol 64:93–103
7. Author-Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ (1991) Clinical risk factors for Alzheimer’s disease: a population-based case-control study. Neurology 41:1393–1397
8. 2 underlies glutamate-dependent inhibition of striatal dopamine release. Proc Natl Acad Sci USA 100:11729–11734
9. Ballmaier M, Narr KL, Toga AW, Elderkin-Thompson V, Thompson PM, Hamilton L, Ebrahim H, Pham D, Heinz A, Kumar A (2008) Hippocampal morphology and distinguishing late-onset from early-onset elderly depression. Am J Psychiatry 165:229–237
10. Bao AM, Swaab DF (2007) Gender difference in age-related number of corticotrophin–releasing hormone-expressing neurons in the human hypothalamic paraventricular nucleus and the role of sex hormones. Neuroendocrinology 95:27–36
11. Bao AM, Fischer DF, Wu Y-H, Hol EM, Balsear R, Unmehopa UA, Zhou JN, Swaab DF (2006) A direct androgenic involvement in the expression of human corticotrophin releasing hormone. Mol Psychiatry 11:567–576
12. Bao A-M, Meynen G, Swaab DF (2008) The stress system in depression and neurodegeneration: focus on the hypothalamus. Brain Res Rev 57:531–553
13. Baumann MH, Rothman RB (2008) Neurobiology of 3-4-Methylenedioxy-methamphetamine MDMA, or “Ecstasy”. In: Karch SB (ed) Neurochemistry of Abused Drugs. CRC Press Taylor & Francis Group, Boca Raton, pp 119–142
14. Baumann B, Danos P, Krell D, Diekmann S, Leschinger A, SStauch R et al (1999) Reduced volume of limbic system-affiliated basal ganglia in mood disorders: preliminary data from a post mortem study. J Neuropsychiatry Clin Neurosci 11:18071–18078
15. Behl C, Lezoualch F, Trapp T, Widmann Skutella T, Holsboer F (1997) Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology 13891:101–105
16. Benes FM, Kwok EW, Vincent SL, Todtenkopf MS (1998) A reduction of not-pyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry 44:88–97
17. Berman RM, Capiello A, Anand A, Oren DA, Henninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354
18. Bhat RV, Budd Haeberlein SL, Avila J (2004) Glycogen synthase kinase-3: a drug target for CNS therapies. J Neurochem 89:1313–1317
19. Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O (2001) Anti-oxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 64:43–51
20. Bindoli A, Rigobello MP, Deeble DJ (1992) Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic Biol Med 13:391–405
21. Bitran D, Shiekh M, Dowd A, Dugan MM, Renda P (1998) Corticosterone is permissive to the anxiolytic effect that results from the blockade of hippocampal mineralocorticoid receptors. Pharmacol Biochem Behav 60:879–887
22. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Müller F-J, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerla LM (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA 106:13594–13599
23. Bregola et al (2000) Different patterns of induction of fibroblast growth factor-2 and brain-derived neurotrophic factor messenger RNAs during kindling epileptogenesis and development of a herpes simplex vector for fibroblast growth factor-2 gene transfer in vivo. Epilepsia 419:s122–s126
24. Bremner DJ (1999) Does stress damage the brain? Biol Psychiatry 45:797–805
25. Brown GW, Harris TO, Hepworthy C (1994) Life events and endogenous depression: a puzzle re-examined. Arch Gen Psychiatry 51:525–534
26. Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S (2010) CBP (CREB binding protein) gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 107:22687–22692
27. Caine ED (1981) “Pseudo-dementia”: current concepts and future directions. Arch Gen Psychiatry 38:1359–1364
28. Cairo G, Recalcati S, Pietrangelo A, Minotti G (2002) The Iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic Biol Med 32:1237–1243
29. Calabrese B, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, Giuffrida Stella AM, Galli F, Butterfield DA (2003) Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 25:437–447
30. Calabrese B, Mancuso C, Marco De, Giuffrida S, Butterfield DA (2007a) Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders. In: Qureshi GA, Parvez SH (eds) Oxidative stress and neurodegenerative disorders. Elsevier, Amsterdam, pp 115–134
31. Calabrese V, Guagliano E, Sapienza M, Panebianco M, Calafao S, Puleo E, Pennisi G, Mancuso C, Butterfield DA, Stella AG (2007b) Redox regulation of cellular stress responses in aging and neurodegenerative disorders: role of vita-genes. Neurochem Res 32:757–773
32. Calapai G, Crupi A, Firenzuoli F et al (2001) Interleukin-6 involvement in antidepressant action of Hypericum Perforatum. Pharmacopsychiatry 34((Supp 1)):S8–S10
33. Canli T, Omura K, Haas BW, Fallgatter A, Constable RT, Lesch KP (2005) Beyond affect: a role for genetic variation of the serotonin transporter in neural activation during a cognitive attention task. Proc Natl Acad Sci USA 102:12224–12229
34. Carneiro AMD, Airey DC, Thompson BA, Zhu C-B, Lu L, Erikson KM, Blakely RD (2009) Functional coding variation in recombinant inbred mouse lines reveals multiple seroronin transporter-associated phenotypes. Proc Natl Acad Sci USA 106:2047–2052
35. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, McClay J, Harrington H, Mill J, Martin J, Braithwaite A, Pouton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386–389
36. Catena-Dell’Osso M, Bellantuono C, Consoli G, BaroniS Rotella F, Marazziti D (2011) Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem 18:245–255
37. Chalmers DT, Desar D, Graham DI, Brooks DN, McCulloch J (1990) Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type. Proc Natl Acad Sci USA 87:1352–1356
38. Chen G, Zeng WZ, Jiang L, Yuan PX, Zhao J, Mangi HK (1999) The mood-stabilizing agents lithium and valproate robustly increase the expression of the neuroprotective protein Bcl-2 in the CNS. J Neurochem 72:879–882
39. Chen KH, Reese EA, Kim H-W, Rapoport SI, Rao JS (2011) Disturbed neurotransmitter transporter expression in Alzheimer’s disease brain. J Alzheimers Dis 26:755–766
40. Coppedè F, Migliore L (2007) Genetic and environmental factors in neurodegenerative diseases. In: Qureshi GA, Parvez SH (eds) Oxidative stress and neurodegenerative disorders. Elsevier, Amsterdam, pp 89–114
41. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:689–695
42. Czéh B, Michaelis T, Watanabe T, Frahm J, Biurrun G, van Kampen M, Gartolomucci A, Fuchs E (2001) Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 98:12796–12801
43. Davis JB, Maher P (1994) Protein kinase C activation inhibits glutamate induced cytotoxicity in a neuronal cell lines. Brain Res 652:169–173
44. Davis KL, Davis BM, Greenwald BS, Mohs RC, Mathe AA, Johns CA, Horvath TB (1986) Cortisol and Alzheimer’s disease, I: basal studies. Am J Psychiatry 143:300–305
45. de Haan JB, Crack PJ, Pritchard MA, Kola I (2007) Down syndrome, antioxidant balance and the “gene dosage effect” hypothesis. In: Qureshi GA, Parvez HS (eds) Oxidative stress and neurodegenerative disorders. Elsevier, Amsterdam, pp 219–236
46. De Kloet ER, Reul JMHM (1987) Feedback action and tonic influence of corticosteroids on brain function: a concept arising from the heterogeneity of brain receptor systems. Psychoneuroendocrinology 12:83–105
47. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M (1998) Brain corticosteroid receptor balance in health and disease. Endocrinol Rev 19:269–301
48. de Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC (1989) Early marker for Alzheimer`s disease: the atrophic hippocampus. Lancet 2:672–673
49. de Leon MJ, George AE, Golomb C, Tarshish A, Convit A, Lluger S, De Santi T, Mc Rae SH, Ferris B, Reisberg C, Ince H, Rusinek M, Bobinski B, Quinn B, Miller DC, Wisniewski HM (1997) Frequency of hippocampal formation atrophy in normal aging and Alzheimer’s disease. Neurobiol Aging 18:1–11
50. Del Rio J, Frenchilla D (2006) Glutamate and depression. In: Schmidt WJ, Reith MEA (eds) Dopamine and glutamate in psychiatric disorders. Humana Press, Totowa, pp 215–236
51. Devenand DP, Sano M, Tang MX et al (1996) Depressed mood and the incidence of Alzheimer’s disease in the elderly living in the community. Arch Gen Psychiatry 53:175–182
52. Doré S, Takahashi M, Ferris CD, Hester LD, Guastella D, Snyder SH (1999) Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc Natl Acad Sci USA 96:2445–2450
53. Drevets WC (2000) Neuroimaging studies of mood disorders. Biol Psychiatry 48:813–829
54. Du J, Wei Y, Liu L, Wang Y, Khairova R, Blumenthal R, Tragon T, Hunsberger JG, Machado-Vieira R, Drevets W, Wang YT, Manji HK (2010) A kinesin signaling complex mediates the ability of GSK-3β to affect mood-associated behaviors. Proc Natl Acad Sci USA 107:11573–11578
55. Dunn AJ (2007) Cytokines, stress, and depression. In: Plotnikoff NP, Faith RE, Murgo AJ, Good RA (eds.) Cytokines, stress and immunity. Taylor & Francis Group, Boca Raton, New York, pp 193–214
56. Engelhardt E, Laks J, Cavalcanti JLS (2003) The glutamatergic system and Alzheimer’s disease. Braz Rev Neurol 39:5–21
57. Ereb I, Naziroglu M, Demirdas A (2007) Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress. Neurochem Res 32:1188–1195
58. Eren I, Nazıroğlu M, Demirdaş A, Çelik Ö, Uğuz Ci A, Altunbaşak A, Özmen I, Uz Efkan (2007) Venlafaxine modulates depression-induced oxidative stress in brain and medulla of rat. Neurochem Res 32:497–505
59. Eriksson PS, Permilieva E, Bjork-Eriksson T et al (1998) Neurogenesis in the adult human hippocampus. Nat Med 4:1313–1317
60. Erkut ZA, Pool G, Swaab DF (1998) Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons. J Clin Endocrinol Metab 83:2066–2073
61. Fiebich BL, Hollig A, Lieb K (2001) Inhibition of substance P-induced cytokine synthesis by St. John’s Wort extracts. Pharmacopsychiatry 34(Suppl 1):S26–S28
62. Fonum F (1984) Glutamate: a neurotransmitter in mammalian brain. J Neurochem 42:1–11
63. Gazzaley AH, Weiland NG, McEwen BS, Morrinson JH (1996) Differential regulation of NMDAR-I mRNA and protein by estradiol in the rat hippocampus. J Neurosci 16:6830–6838
64. Geerlings MI, Schoevers RA, Beekman ATF, Jonker C, Deeg DJH, Schmand B, Adèr HJ, Bouter LM, Van Tilburg W (2000) Depression and risk of cognitive decline and Alzheimer’s disease: results of two prospective community-based studies in The Netherlands. Brit J Psychiatry 76:568–5754
65. Geerlings, den Heijer T, Koudstaal PJ, Hofman A, Breteler MMB (2008) History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer’s disease. Neurology 70:1258–1264
66. Ghosal K, Vogt DL, Liang M, Shen y, Lamb BT, Sanjay WP (2009) Alzheimer’s disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci USA 106:18367–18372
67. Gille G, Riederer P (1995) Dopamine and neurodegeneration. In: Schmidt WJ, Reith MEA (eds) Dopamine and glutamate in psychiatric disorders. Humana Press, Totowa, pp 415–445
68. Goodman Y, Bruce AJ, Cheng B, Mattson MP (1996) Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J Neurochemi 66:1836–1844
69. Gorczynski R, Stanley J (1999) Biological activities of cytokines that signal via the JAK/STAT pathway. In: Gorczynski R, Stanley J (eds) Clinical immunology: an introductory text. Landes Bioscience, Jorgetown, pp 117–120
70. Gould E, Tanapat P, McEwen BS, Flugge G, Fuchs E (1998) Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci USA 95:3168–3171
71. Green RCL, Cupples A, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D (2003) Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol 60:753–759
72. Greene JG, Greenamyre JT (1995) Exacerbation of NMDA, AMPA and l-glutamate excitotoxicity by the succinate dehydrogenase inhibitor malonate. J Neurochem 64:2332–2338
73. Gruenberg AM, Goldstein RD, Pincus HA (2005) Classification of depression: research and diagnostic criteria: DSM-IV and ICD-10. In: Licinio J, Wong M-L (eds) Biology of Depression: From Novel Insights to therapeutic Strategies. Wiley, Weinheim, pp 1–12
74. Gudelsky GA, Yamamoto BK (2003) Neuropharmacology and neurotoxicity of 3,4-methylene-dioximethamphetamine (MDMA). Methods Mol Med 79:55–73
75. Gwag BJ, Lobner D, Koh JY, Wie MB, Choi DW (1995) Blockade of glutamate receptors unmasks neuronal apoptosis after oxygen-glucose deprivation in vitro. Neuroscience 68:615–619
76. Haines JL, Bailey LR, Grubber JM, Hedges D, Hall JL, West S, Santoro L, Kemmerer B, Sauders A, Roses AD, Small GW, et al (2002) A genomic search for Alzheimer’s disease genes. In: Iqbal K, Sisodia S, Winblad B (eds) Alzheimer’s disease: advances in etiology, pathogenesis and therapeutics. John Wiley and Sons, Ltd., Wiley Online Library
77. Halliwell B, Gutteridge JMC (1993) Free radicals in biology and medicine. Oxford University Press, New York
78. Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I (1997) Twenty-four hour cortisol release profiles in patients with Alzheimer’s and Parkinson’s disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging 18:285–289
79. Hattori A, Luo Y, Umegaki H, Munoz J, Roth GS (1998) Intrastriatal injection of dopamine results in DNA damage and apoptosis in rats. NeuroReport 9:2569–2572
80. Herman JP, Cullinan WE (1997) Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 20:78–84
81. Herman JP, Patel PD, Akil H, Watson SJ (1989) Localization and regulation of glucocorticoid and mineralocorticoid receptor messenger RNAs in the hippocampal formation of the rat. Mol Endocrinol 3:1886–1894
82. Holmes A, Lit Q, Murphy DL, Gold D, Crawley JN (2003) Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav 2:365–380
83. Holsboer F, Lauer CJ, Schreiber W, Krieg J-C (1995) Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familiar risk for affective disorders. Neuroendocrinology 62:340–347
84. Hoogendijk W JG, Meynen G, Endertc E, Hofman MA, Swaab DF (2006) Increased cerebrospinal fluid cortisol level in Alzheimer’s disease is not related to depression. Neurobiol Aging 27:780.e1–780.e2
85. Huang X, Awood CS, Hartshorn MA et al (1999) The Aβ peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochem 38:7609–7616
86. Issa AM, Rowe W, Gauthier S, Meaney MJ (1990) Hypothalamic-pituitary-adrenal activity in aged, cognitively impaired and cognitively unimpaired rats. J Neurosci 10:3247–3254
87. Jacobson L, Sapolski RM (1991) The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenal axis. Endocr Rev 12:118–134
88. Jang J-H, Surh Y-J (2005) Implications of inflammatory stress in Alzheimer’s disease. In: Packer L, Surh Y-J (eds) Oxidative stress, inflammation and health. Taylor and Francis Group, Boca Raton, pp 445–470
89. Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, Wilson WD, Siao g, Blanchi B, Sun YE, Ye K (2010) A selective TrkB agonist with potent neurotrophic activities by 7—dihydroxyflavone. Proc Natl Acad Sci USA 107:2687–2692
90. Jellinger KA (2007) Advances in our understanding of neurodegeneration. In: Qureshi GA, Parvez SH (eds) Oxidative stress and neurodegenerative disorders. Elsevier, Amsterdam, pp 1–58
91. Jennings KA, Loder MK, Sheward WJ, Pei Q, Deacon RMJ, Benson MA, Olverman HJ, Hastie ND, Harmar AJ, Shen S, Sharp T (2006) Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission. J Neurosci 26:8955–8964
92. Jimenez DR, Velez PC, Pinxteren J, De Potter W, Ebinger G, Vauquelin G (1993) Binding of serotonin and dopamine to ‘serotonin binding proteins’ in bovine frontal cortex: evidence for iron-induced oxidative mechanisms. Eur J Pharmacol 247:11–21
93. Kaltschmidt PA, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C (1997) Transcriptor factor NF-kβ is activated in primary neurons by amyloid-β peptides and in neurons surrounding early plaques from patients with Alzheimer’s disease. Proc Natl Acad Sci USA 94:2642–2647
94. Kessing LB, Nilsson FM (2003) Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord 73:261–269
95. Khan TK, Alkon DL (2006) An internally controlled peripheral biomarker for Alzheimer’s disease: Erk1 and Erk2 responses to the inflammatory signal bradikinin. Proc Natl Acad Sci USA 103:13203–13203
96. Koo Ko, Russi JW, Ferguson D, Nestler EJ, Duman RS (2010) Nuclear factor—kβ is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci USA 107:2669–2674
97. Krauss G (2001) Intracellular signal transduction: the protein cascades of the MAP kinase pathways. In: Krauss, G (ed) Biochemistry of signal transduction and regulation, 2nd edn. Wiley, Wheinheim, p:350
98. Kücükakin B, Gögenur I, Reiter RJ, Rosenberg J (2009) Oxidative stress in relation to surgery: is there a role for the antioxidant melatonin? J Surg Res 152:338–347
99. Kuhn DM, Geddes TJ (2000) Molecular footprints of neurotoxic amphetamine action. Ann N Y Acad Sci 914:92–103
100. Kumar A, Newberg A, Alavi A, Berlin J, Smith R, Reivich M (1993) Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: a preliminary positron emission tomography study. Proc Natl Acad Sci USA 90:7019–7023
101. Kunkin J, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA (2004) Increased hippocampal neurogenesis in Alzheimer’s disease. Proc Natl Acad Sci USA 101:343–347
102. Landfield PW (1994) The role of glucocorticoids in brain aging and Alzheimer’s disease: an integrative physiological hypothesis. Exp Gerontol 29:3–11
103. Landfield PW, Linch G (1978) Hippocampal aging and adrenocorticoids; quantitative correlations. Science 202:1098–1102
104. Lawrence MS, Sapolsky RM (1994) Glucocorticoids accelerate ATP loss following metabolic insults in cultured hippocampal neurons. Brain Res 646:303–306
105. Le DA, Lipton SA (2001) Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging. Drug Aging 18:717–724
106. Lenox RH, Hahn C-G (2000) Overview of the mechanism of action of lithium in the brain: fifty-year update. J Clin Psychiatry 61((Supp 9)):5–15
107. Li H-L, Wang H-H, Liu S-J, Deng Y-Q, Zhang Y-J, Tian Q, Wang X-C, Chen X-Q, Yang Y, Zhang J-Y, Wang C, Xu H, Liao F-F, Wang J-Z (2007) Phosphorylation of tau antagonizes apoptosis by stabilizing β-catenin, a mechanism involved in Alzheimer’s neurodegeneration. Proc Natl Acad Sci USA 104:3591–3596
108. Linholm D et al (1994) Activity-dependent and hormonal regulation of neurotrophin mRNA levels in the brain-implications for neuronal plasticity. J Neurobiol 25:1362–1372
109. Littleljohn D, Mangano E, Hayley S (2010) Common pathways to neurodegeneration and co-morbid depression. In: Ritsner MS (ed) Brain protection in schizophrenia, mood and cognitive disorders. Springer, Amsterdam, pp 185–242
110. Liu J, Ames BN (2006) Mitochondrial nutrients: reducing mitochondrial decay to delay or treat cognitive dysfunction, Alzheimer’s disease, and Parkinson’s disease. In: Luo Y, Packer L (eds) Oxidative stress and age-related neurodegeneration. Taylor & Francis Group, Boca Raton, pp 59–106
111. Liu J, Wang X, Shigenaga MK, Yeo HC, Mori A, Ames BN (1996) Immobilization stress causes oxidative damage to lipid, protein, and DNA in the brain of rats. FASEB J 10:1532–1538
112. Liu RY, Zhou JN, Hoogendijk WJ, van Heerikhuize J, Kamphorst W, Unmehopa UA, Hofman MA, Swab DF (2000) Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression. J Neuropathol Exp Neurol 59:314–322
113. Liu RY, Unmehopa UA, Zhou JN, Swaab DF (2006a) Glucocorticoids suppress vasopressin gene expression in human supra-chiasmatic nucleus. J Steroid Biochem Mol Biol 98:248–253
114. Liu Z, Zhu F, Wang G, Xiao Z, Wang H, Tang J, Wang X, Qiu D, Liu W, Cao Z, Li W (2006b) Association of corticotropin-releasing hormone receptor-1 gene SNP and haplotype with major depression. Neurosci Lett 404:358–362
115. Lloyd RV (1995) Mechanism of the manganese-catalyzed auto-oxidation of dopamine. Chem Res Toxicol 8:111–116
116. Luo Y, Hattori A, Munoz J, Qin ZH, Roth GS (1999) Intra-striatal dopamine injection induces apoptosis through oxidation-involved activation of transcription factors AP-1 and NF-kappa B in rats. Mol Pharmacol 56:254–264
117. Lupien SJ, McEwen BS (1997) The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Res Rev 24:1–27
118. Lupien SJ, de Leon M, de Santi S, Convit A, Tarshish C, Nair NPV, Thakur M, McEewen BS, Hauger RL, Meaney MJ (1990) Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci 1:69–73
119. Lupien SJ et al (1994) Basal cortisol levels and cognitive deficits in human aging. J Neurosci 14:2893–2903
120. Lupien SJ et al (1995) Longitudinal study of basal cortisol levels in healthy elderly subjects; evidence for sub-groups. Neurobiol Aging 17:95–105
121. Lupien SJ, de Leon M, de Santi S, Convit A, Tarshish C, Nair NPV, Thakur M, McEwen BS, Hauger RL, Meaney MJ (1998) Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci 1:69–73
122. Macdonald J, Galley HF, Webster NR (2003) Oxidative stress and gene expression in sepsis. Br J Anaesth 90:221–232
123. Maes M, Lin A-h, Delmeire L, Gastel AV, Kenis G, De Jongh R, Bosmans E (1999) Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in post-traumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry 45:833–839
124. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M (2009) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24:27–53
125. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J (2011) Depression’s multiple comorbidities explained by (neuro) inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 32:7–24
126. Magarinos AM, Berdugo JM, McEwen BS (1997) Chronic stress alters synaptic terminal structure in hippocampus. Proc Natl Acad Sci USA 94:14002–14008
127. Mahler P, Davis JB (1996) The role of monoamine metabolism in oxidative glutamate toxicity. J Neurosci 16:6934
128. Mangi HK, Moore GG, Chen G (2000) Clinical and pre-clinical evidence for the neurotrophic effects of mood stabilizers: implications of the pathophysiology and treatment of manic-depressive diseases. Biol Psychiatry 48:740–754
129. Manji HK, Moore GJ, Chen G (1999) Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46:929–940
130. Manji HK, Moore GJ, Chen G (2000) Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 61:82–96
131. Martinowich K, Manji H, Lu B (2007) New insights into BDNF function in depression and anxiety. Nat Neurosci 10:609–615
132. Matrone C, Ciotti MT, Mercanti CD, Marolda R, Calissano P (2008) NGF (Nerve Growth Factor) and BDNF signaling control amyloidogenic route and Aβ production in hippocampal neurons. Proc Natl Acad Sci USA 105:13139–13144
133. Mayberg HS, Lewis PJ, Regenold W, Wagner HNJ (1994) Paralimbic hypoperfusion in unipolar depression. J Nucl Med 35:929–934
134. Mazurek MF, Growdon JH, Beal MF, Martin JB (1986) CSF vasopressin concentration is reduced in Alzheimer’s disease. Neurol 36:1133–1137
135. Mazzulli JR, Lind S, Ischiropoulos H (2006) Reactive oxygen and nitrogen species: weapons of neuronal destruction. In: Luo Y, Packer L (eds) Oxidative stress and age-related neurodegeneration. Taylor & Francis Group, Boca Raton, pp 107–120
136. McEwen BS (1999) Stress and hippocampal plasticity. Annu Rev Neurosci 22:105–122
137. McEwen BS, Magarinos AM (2001) Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders. Hum Psychopharmacol 16:S7–S19
138. McIntosh LJ, Hong KE, Sapolsky RM (1995) High glucocorticoid levels decrease some antioxidant enzyme activities in the adult rat brain. Soc Neurosci Abstr 21:2129
139. Meynen G, Unmehopa UA, Hofman MA, Swaab DF, Hoogendijk WJ (2007) Hypothalamic oxytocin mRNA expression and melancholic depression. Mol Psychiatry 12:118–119
140. Milne GL, Gao L, Brooks JD, Morrow JD (2008) The role of oxidative stress in diseases associated with overweight and obesity. In: Packer L, Sies H (eds) Oxidative stress and inflammatory mechanisms in obesity, diabetes, and the metabolic syndrome. Taylor & Francis Group, Boca Raton, pp 33–36
141. Mlynarik M, Zelena D, Bagdy G, Makara GB, Jezova D (2007) Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm Behav 51:395–405
142. Moore GH, Bebchuk JM, Wilds IB, Chen G, Manji HK (2000) Lithium-induced increase in human brain grey matter. The Lancet 356:1241–1242
143. Moreira PI, Zhu X, Nunomura A, Smith MA, Perry J (2006) Antioxidant therapies in the prevention and treatment of Alzheimer disease. In: Luo Y, Packer L (eds) Oxidative stress and age-related neurodegeneration. Taylor & Francis Group, Boca Raton, pp 131–146
144. Moreira PI, Nunomura A, Honda K, Aliev G, Casadeus G, Zhu X, Smith MA, Perry G (2007) The key role of oxidative stress in Alzheimer’s disease. In: Qureshi GA, Parvez SH (eds) Oxidative stress and neurodegenerative disorders. Elsevier, Amsterdam, pp 267–282
145. Mory E, Danysz W, Quack G (1993) Potential antidepressant properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 72:394–397
146. Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT (1989) Glutamate toxicity in a neuronal cell line involves inhibition of cysteine transport leading to oxidative stress. Neuron 2:1547–1558
147. Murray RK (2003) Red & white blood cells. In: Murray RK, Granner DK, Mayes PA, Rodwell VW (eds) Harper’s illustrated biochemistry. Lange Medical Books/McGraw-Hill, New York, pp 611–613
148. Myint A-M, Kim Y-K (2003) Cytokine-serotonin interactions through indoleamine-2, 3-dioxygenase: a neurodegenerative hypothesis of depression. Med Hypo 61:519–525
149. Naoi M, Maruyama W, Shamoto-Nagai M, Kato Y, Tanaka M (2005) Oxidative stress in mitochondria: the involvement in neurodegenerative diseases. In: Packer L, Surh Y-J (eds) Oxidative stress, inflammation and health. Taylor and Francis Group, Boca Raton, pp 423–444
150. Nitsch R, Frotscher M (1992) Reduction of posttraumatic trans-neuronal “early gene” activation and dendritic atrophy by the N-methyl-D-aspartate receptor antagonist MK-801. Proc Natl Acad Sci USA 89:5197–5200
151. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gay K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102:6990–6995
152. Nunomura A, Perry G, Aliev G et al (2001) Oxidative damage is the earliest event in Alzheimer’s disease. J Neuropathol Exp Neurol 60:759–767
153. O’Brien JT, Ames D, Schweitzer I, Colman P, Desmond P, Tress B (1996) Clinical and magnetic resonance imaging correlates of hypothalamic-pituitary-adrenal axis function in depression and Alzheimer’s disease. Br J Psychiatry 168:679–687
154. Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ (1993) Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms and prevention. J Neurosci 13:1441–1453
155. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D (2006) Depression and risk for Alzheimer disease. Arch Gen Psychiatry 63:530–538
156. Parker G (2000) Classifying depression? Should paradigms lost be regained? Am J Psychiatry 157:1195–1203
157. Patapoutian A, Reichardt LF (2001) Trk receptors: mediators of neurotrophin action. Cur Opin Neurobiol 11:272–280
158. Paul IA, Skolnick P (2003) Glutamate and depression: clinical and pre-clinical studies. Ann N Y Acad Sci 1003:250–271
159. Pedrosa R, Soares-da-Silva P (2002) Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Braz J Pharmacol 137:1305–1313
160. Perry G, Nunomura A, Raina AK, Smith MA (2000a) Aβ junkies. The Lancet 355:757
161. Perry G, Raina AK, Nunomura A et al (2000b) How important is oxidative damage? Lessons from Alzheimer’s disease. Free Radic Biol Med 28:831–834
162. Perry G, Cash AD, Srinivas R, Smith MA (2002) Metals and oxidative homeostasis in Alzheimer’s disease. Drug Dev Res 56:293–299
163. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP (2004) Investigation of serotonin-related genes in antidepressant responses. Mol Psychiatry 9:879–889
164. Plotsky PM (1991) Pathways to the secretion of adrenocorticotropin: a view from the portal. J Neuroendocrinol 3:1–9
165. Pomara N, Sidtis J (2009) Does cortical thinning in persons at increased risk for major depression also increase their risk for Alzheimer’s disease? Proc Natl Acad Sci USA 106:E82
166. Pomara N, Stanley M, Rhiew HB, Bagne CA, Deptula D, Galloway MP, Tanimoto K, Verebey K, Tamminga CA (1988) Loss of the cortisol response to naltrexone in Alzheimer’s disease. Biol Psychiatry 23:726–733
167. Porter NM, Landsfield PW (1998) Stress hormones and brain aging; adding injury to insult? Nat Neurosci 1:3–4
168. Radley JJ, Sawchenko PE (2011) A common substrate for prefrontal and hippocampal inhibition of the neuroendocrine stress response. J Neurosci 31:9683–9695
169. Raison CL, Purselle DC, Capuron L, Miller AH (2005) Treatment of depression in medical illness. In: Licinio J, Wong M-L (eds) Biology of depression: from novel insights to therapeutic strategies. Wiley, Weinheim, pp 253–278
170. Rajkowska G (2000) Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 48:766–777
171. Rasmuson A, Nasman V, Carlstrom K, Olsson T (2002) Increased levels of adrenocortical and gonadal hormones in mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 13:74–79
172. Reisberg B, Doody R, Stöffler A, Schnutt F, Ferris S, Möbius H (2003) Memantine in moderate to severe Alzheimer’s disease. N Engl J Med 348:1333–1342
173. Roca CA, Schmidt PJ, Deuster PA, Danaceau MA, Altemus M, Petnam K, Chrousos GP, Nieman LK, Rubinow DR (2005) Sex-related differences in stimulated hypothalamic-pituitary-adrenal axis during induced gonadal suppression. J Clin Endocrinol and Metab 90:4224–4231
174. Rodrigues R, Bonda DJ, Perry G, Castellani RJ, Casadesus G, Lee H-g, Lee H-P, Wang X, Zhu X, Petersen RB, Smith MA (2010) Oxidative stress and neurodegeneration: an inevitable consequence of aging: implications for therapy. In: Ritsner MS (ed) Brain protection in schizophrenia, mood and cognitive disorders. Springer, Netherlands, pp 305–325
175. Rogóz Z, Skuza G, Maj J, Danysz W (2002) Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 42:1024–1030
176. Roy BN, Reid RL, Van Vugt DA (1999) The effects of estrogen and progesterone on corticotropin-releasing hormone and arginine vasopressin messenger ribonucleic acid levels in the paraventricular nucleus and supraoptic nucleus of the rhesus monkey. Endocrinology 140:2191–2198
177. Sapolski MS (2000) The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 48:766–777
178. Sapolsky RM (2001) Depression, antidepressants, and the shrinking hippocampus. Proc Natl Acad Sci USA 98:12320–12322
179. Sapolsky RM, Uno H, Rebert CS, Finch CE (1990) Hippocampal damage associated with prolonged glucocorticoid exposure. J Neurosci 10:2897–2902
180. Scolville WB, Milner B (1957) Hippocampal damage and memory dysfunction. J Neurol Psychiatry 20:11–21
181. Segal RA (2003) Selectivity in neurotrophin signaling: theme and variations. Annu Rev Neurosci 26:299–330
182. Shanmugham B, Alexopoulus G (2005) Geriatric depression. In: Licinio H, Wong M-L (eds) Biology of depression: from novel insights to therapeutic strategies. Willey, Weinheim, pp 319–340
183. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW (1996) Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 93:3908–3913
184. Shorter E, Fink M (2010) Cortisol. In: Shorter E, Fink M (eds) Endocrine psychiatry: solving the riddle of melancholia. Oxford University Press, London, pp 31–50
185. Smith MA, Drew KL, Nunomura A, Takeda A, Hirai K, Zhu X, Atwood CS, Raina AK, Rottkamp CA, Sayre LM, Friedland RP, Perry G (2002) Amyloid-β, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs? Neurochem Int 40:527–531
186. Snyder SH (2011) Serotonin, cytokines, p11, and depression. Proc Natl Acad Sci USA 108:8923–8924
187. Sopolsky RM, Krey LC, McEwen BS (1986) The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocrinol Rev 7:284–301
188. Sotiropoulos I, Catania C, Pinto LG, Silvia R, Pollerber GE, Takashima A, Sousa N, Almeida OFX (2011) Stress acts cumulatively to precipitate Alzheimer’s disease-like tau pathology and cognitive deficits. J Neurosci 21:7840–7847
189. Sprague JE, Everman SL, Nichols DE (1998) An integrated hypothesis for the serotonergic axonal loss induced by 3, 4-methylenedioxymethamphetamine. Neurotoxicology 19:427–441
190. Starkstein SE, Jorge R, Mizrahi R, Robinson RG (2005) The construct of minor and major depression in Alzheimer’s disease. Am J Psychiatry 162:2086–2093
191. Stokes KY, Tailor A, Granger DN (2005) Role of oxidative stress in hypercholesterolemia-Induced inflammation. In: Surh Y-J, Packer L (eds) Oxidative stress, inflammation and health. Taylor and Francis Group, Boca Raton, pp 221–244
192. Swaab DA, Bao A-M (2011) (Re-) activation of neurons in aging and dementia: lessons from the hypothalamus. Exp Gerontol 46:178–184
193. Swaab DF, Gao AM, Lucassen PJ (2005) The stress system in the human brain in depression and neurodegeneration. Res Rev 4:141–194
194. Terracciano A, Lobina M, Peras MG, Mulas A, Cannas A, Meirelles O, Sutin AR, Zonderman AB, Uda M, Crisponi L, Schlessinger D (2011) Neuroticism, depressive symptoms, and serum BDNF. Psychosom Med 73:638–642
195. Thomas AJ, Morris C, Davis S, Jackson E, Harrison R, O’brien JT (2007) Soluble cell adhesion molecules in late-life depression. Int Psychogeriatr 4:1–7
196. Toro G, Rodrigo R (2009) Oxidative stress, basic overview. In: Rodrigo R (ed) Oxidative stress and antioxidants: their role in human disease. Nova Science Publishers Inc., New York, pp 1–24
197. Vallone D, Picetti R, Borrelli E (2000) Structure and function of dopamine receptors. Neurosci Biobehav Rev 24:125–132
198. Vincent SL, Todtenkopf MS, Benes FM (1997) A comparison of the density of pyramidal and not pyramidal neurons in the anterior cingulate cortex of schizophrenics and manic-depressives. Soc Neurosci 23:2199
199. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P (2011) Antidepressant effects of selective serotonin reuptake inhibitors (SSRI) are attenuated by anti-inflammatory drugs in mice and humans. Proc Natl Acad Sci USA 108:9262–9267
200. Weingarten P, Bermak J, Zhou QY (2001) Evidence for non-oxidative dopamine cytotoxicity: potent activation of NF-kappa B and lack of protection by anti-oxidants. J Neurochem 76:1794–1804
201. Wilson RS, Barnes LL, Mendes de Leon CF, Aggarwal NT, Schneider JA, Bach J, Pilat J, Beckett LA, Arnold SE, Evans DA, Bennett DA (2002) Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology 59:364–370
202. Woo NH, Teng HK, Siao C-J, Chiaruttini C, Pang PT, Milner TA, Hempstead BL, Lu B (2005) Activation of p75NTR by pro-BDNF facilitates hippocampal long-term depression. Nat Neurosci 8:1069–1077
203. Wooleley CS, Weiland NG, McEwen BS, Schwartzkroin PA (1997) Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J Neurosci 17:1848–1859
204. Woolley CS, Gould E, Frankfurt M, McEwen CS (1990) Naturally occurring fluctuation in dendritic spine density on adult hippocampal pyramidal neurons. J Neurosci 10:4035–4039
205. Woolley CS, Gould E, Sakay R, Spencer R, McEwen BS (1998) Effects of aldosterone or RU2862 treatment on adrenalectomy-induced cell death in the dentate gyrus of the adult rat. Brain Res 554:312–315
206. Wright SL, Persad C (2007) Distinguishing between depression and dementia in older persons: neuropsychological and neuropathological correlates. J Geriatr Psychiatry Neurol 20:189–198
207. Wurster AL, Grusby MJ (2004) Cytokines. In: Lennarz WJ, Lane MD (eds) Encyclopedia of biological chemistry. Elsevier Inc, Oxford, pp 550–555
208. Zaudig M (2005) The prodromes and early detection of Alzheimer’s disease. In: Maj M, Lopez-Ibor JJ, Sartorius N, Sato M, Okasha A (eds) Early detection and management of mental disorders. Wiley, England, pp 277–294